The New Frontier of Cancer Care: Six Forces Reshaping Oncology

What you’ll learn:

Oncology is at an inflection point. Genomics, artificial intelligence, drug development, and care delivery are converging. Cancers once considered death sentences are becoming manageable conditions.

Six trends are driving this transformation. Each is significant on its own. Together, they are rewriting the rules of cancer care.

1. The Science Is Moving at Unprecedented Speed

Oncology innovation is accelerating at a historic pace. More than 60% of all FDA approvals since 2000 have been in oncology. Over 2,250 phase 3 oncology trials were ongoing in 2021. 85% of accelerated approvals granted over the last decade were for oncology products.

That pace has reshaped clinical practice in ways that even experienced oncologists find challenging. A category once organized around broad tumor types such as lung, breast, and colon cancer now operates at the level of molecular subtypes, biomarker expression, and genomic signatures, with two-thirds of all FDA oncology approvals now tied to a specific biomarker. 

When oncologists are overwhelmed, they default to what is familiar and comfortable for them, which can impede their ability to learn about and consider a new brand for their practice. In this status quo bias, the oncology brands most likely to break through are the ones that are most engaging and make it easiest for a busy clinician to understand, trust, and act upon.

2. The Blood Draw That Could Change Everything

One of the most transformative developments in oncology is the rise of liquid biopsy technology. Using a simple blood draw, these tests can identify circulating tumor DNA, cancer cells, or other cancer-related biomarkers. It can detect cancer signals years before a patient would typically experience symptoms.

Detecting cancer at Stage I rather than Stage IV can be the difference between a cure and palliation. As screening and detection move upstream, patient populations will shift toward earlier-stage disease management with different profiles, prognoses, and treatment pathways. 

But access is not guaranteed, with some tests costing close to $1,000 out-of-pocket, and are not covered by Medicare or most private insurance plans. Underserved and disadvantaged patients, without access to lipid biopsies, will continue to be diagnosed later, exacerbating mortality and morbidity rates and highlighting the need for health equity.

3. Precision Medicine Has Become Operational

Precision medicine has long been oncology’s goal. What’s changed is that it has become standard practice. Where oncologists once prescribed based on tumor type and stage, they now factor in genomic profile, resistance patterns, and biomarker status. The result is a treatment landscape defined by specificity. Antibody-drug conjugates, bispecific antibodies, and CAR-T therapies are each engineered to hit a molecular target that broad chemotherapy never could. Treatment selection has shifted from “which drug?” to “which drug, for which genomic profile, and in what sequence relative to my other options?”

This specificity creates enormous promise, but also operational complexity. Many tumors now carry multiple actionable biomarkers. Multiple therapies may target the same biomarker, pathway, or mechanism of action. And as more targeted options enter the market, sequencing decisions become harder for oncologists to navigate.

For brand teams, clear positioning is more important than ever. Teams that launch without a defensible answer to “why this drug, for this patient profile, at this line of therapy?” risk being lost in an increasingly crowded and confusing marketplace.

4. Cancer Is Increasingly a Chronic Disease

As life expectancy rises and the baby boom generation ages, the number of people living with cancer will continue to grow. Combined with treatments that keep patients alive longer, the result is cancer shifting from an acute event into a chronic condition, managed over months, years, or even decades. 

This shift carries implications across the care continuum. Long-term treatment regimens can create a sustained financial burden. Quality of life increasingly competes with survival as a primary clinical goal. The relationship between patients and care teams becomes longitudinal rather than episodic, requiring holistic support that spans emotional, nutritional, social, and financial dimensions over time. It is also changing how oncologists evaluate treatment decisions. When patients remain on therapy for years rather than months, long-term safety, tolerability, adherence, and cumulative burden become more central to clinical decision-making.

Long-term therapy means longer-term relationships for brands with HCPs, patients, care teams, and payers. Oncology launches need to consider both short-term and long-term strategies. Patient support programs must account for years of adherence, financial strain, and quality-of-life management, not just the initial critical days on treatment.

5. Inequity and Financial Toxicity Are Compounding Each Other

Oncology’s most powerful advances are not reaching patients equally. Gaps across race, income, and geography are widening as the field moves faster.

As innovation accelerates, those gaps risk widening. Some novel therapies cost more than $400,000 yearly. High out-of-pocket costs and coverage gaps lead patients to delay or discontinue care. While biosimilars offer partial relief, systemic drug pricing solutions remain elusive. As precision medicine subdivides oncology into ever-narrower categories, its most powerful advances risk reaching only the patients already positioned to access them. Furthermore, research shows that insurers are being more strict than ever and covering fewer drugs or requiring prior authorizations for many drugs coming to market.  

While a compelling and differentiating clinical profile is, of course, important, access is more critical than ever to a successful brand launch. Coverage status, formulary position, and prior authorization pathways are essential factors—particularly when established, lower-cost alternatives already exist. Ultimately, coverage and formulary status and guidelines are more critical than ever to a brand launch success. Payer strategy needs to be overtly integrated into brand planning so oncologists and patients can get access to the great drug that is being developed.

6. AI Is Beginning to Rewire the Infrastructure of Cancer Care

AI is entering oncology at every level. From drug discovery and genomic data analysis to treatment sequencing and clinical decision support, this work is no longer theoretical and is being built and validated globally. By drawing on real-world datasets, AI platforms can identify patterns across thousands of patients that no individual clinician could detect, helping oncologists navigate an increasingly complex treatment landscape with greater confidence. 50% of oncologists and 50% of people living with cancer already report using AI to learn about treatments.

AI is shaping what oncologists and patients know before they speak with a sales rep or read branded content. The use of LLMs like ChatGPT or Gemini are becoming the primary source to search for information. Generative engine optimization (GEO) will be important to ensure your brand content is getting the visibility it deserves for inclusion in those AI search summaries. Brands that ignore this risk are entering a conversation where the other side is already informed and potentially misinformed. Understanding how AI surfaces information about your therapy is now a key performance metric for all online communications.

Navigating What’s Next

As these six trends are interrelated, the future of oncology will not be defined solely by innovation. Instead, it will be defined by how well that innovation is translated into decisions, access, trust, and sustained support.

The same aging population driving the chronic disease shift is also straining the health systems that need to deliver precision therapies equitably. The AI tools that could accelerate treatment sequencing are also the ones that could widen access gaps if they are not designed with underserved communities in mind.

For oncology brands, the mandate is clear. It will be a balance of the biology, the patient, the system, and an acknowledgment of the speed at which all are changing.

Klick Health is the world’s largest independent commercialization partner for life sciences and a leading full-service pharma marketing partner, serving as agency of record for leading pharma, biotech, and healthcare brands. Klick’s specialized offerings are rooted in deep medical and scientific understanding, including market insights, award-winning creative, and proprietary AI and data models to craft impactful brand narratives and seamless customer journeys. Backed by nearly 250 medical experts and advanced healthcare analytics, Klick delivers integrated marketing strategy and communications, from new product launch strategy to MLR review with real-world evidence, helping brands thrive in today’s complex healthcare landscape. Learn more at Klick.com.